Allogene Therapeutics, Inc. (ALLO)
2.07
-0.15
(-6.76%)
USD |
NASDAQ |
Mar 20, 16:00
2.11
+0.04
(+1.93%)
After-Hours: 20:00
Allogene Therapeutics Enterprise Value : 337.66M for March 20, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 2.007B |
| Inovio Pharmaceuticals, Inc. | 60.02M |
| Vaxart, Inc. | 102.77M |
| Capricor Therapeutics, Inc. | 1.373B |
| Agenus, Inc. | 467.61M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -38.81M |
| Total Expenses (Quarterly) | 38.81M |
| EPS Diluted (Quarterly) | -0.1717 |
| Earnings Yield | -41.94% |
| Normalized Earnings Yield | -41.57 |